Carolina L Haass-Koffler

Prof. Carolina L Haass-Koffler

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2018 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
CHCarolina L Haass-Koffler
Carolina L Haass-Koffler
RSRobert M. Swift
Robert M. Swift
LLLorenzo Leggio
Lorenzo Leggio

1 August 2017 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
CHCarolina L Haass-Koffler
Carolina L Haass-Koffler
KGKimberly Goodyear
Kimberly Goodyear
WZWilliam H. Zywiak
William H. Zywiak
MMMolly Magill
Molly Magill
SESarah E. Eltinge
Sarah E. Eltinge
LLLorenzo Leggio
Lorenzo Leggio

30 September 2020 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
CHCarolina L Haass-Koffler
Carolina L Haass-Koffler
DPDaria Piacentino
Daria Piacentino
XLXiaobai Li
Xiaobai Li
VLVictoria M. Long
Victoria M. Long
MLMary R. Lee
Mary R. Lee
LLLorenzo Leggio
Lorenzo Leggio

15 November 2016 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
CHCarolina L Haass-Koffler
Carolina L Haass-Koffler
AHA T Henry
A T Henry
GMG Melkus
G Melkus
JSJ A Simms
J A Simms
MNM Naemmuddin
M Naemmuddin
LLLorenzo Leggio
Lorenzo Leggio
The corticotropin releasing factor (CRF) exerts its effects by acting on its receptors and on the binding protein (CRFBP), and has been implicated in alcohol use disorder (AUD). Therefore, identification of the exact contribution of each protein that mediates CRF effects is necessary to design effective therapeutic strategies for AUD. A series ofin vitro/in vivoexperiments across different species were performed to define the biological discrete role of CRFBP in AUD. First, to establish the CRFBP role in receptor signaling, we developed a novel chimeric cell-based assay and showed that CFRBP full length can stably be expressed on the plasma membrane. We discovered that only CRFBP(10 kD) fragment is able to potentiate CRF-intracellular Ca2+release. We provide evidence thatCRHBPgene loss increased ethanol consumption in mice. Then, we demonstrate that selective reduction ofCRHBPexpression in the center nucleus of the amygdala (CeA) decreases ethanol consumption in ethanol-dependent rats. CRFBP amygdalar downregulation, however, does not attenuate yohimbine-induced ethanol self-administration. This effect was associated with decreased hemodynamic brain activity in the CRFBP-downregulated CeA and increased hemodynamic activity in the caudate putamen during yohimbine administration. Finally, in alcohol-dependent patients, genetic variants related to the CRFBP(10 kD) fragment were associated with greater risk for alcoholism and anxiety, while other genetic variants were associated with reduced risk for anxiety. Taken together, our data provide evidence that CRFBP may possess both inhibitory and excitatory roles and may represent a novel pharmacological target for the treatment of AUD.

21 December 2017 in Alcohol and Alcoholism
Verified
Journal Article
Open access
PDF file
CHCarolina L Haass-Koffler
Carolina L Haass-Koffler
KGKimberly Goodyear
Kimberly Goodyear
WZWilliam H Zywiak
William H Zywiak
LLLorenzo Leggio
Lorenzo Leggio
GKGeorge A Kenna
George A Kenna
RSRobert M Swift
Robert M Swift
The goal of this study was to evaluate the efficacy of topiramate up to 200 mg/day and of aripiprazole up to 15 mg/day, alone and combined, in reducing alcohol-related outcomes in a human laboratory study. This was a 5 week, between-subject, double-blind, placebo-controlled human laboratory study with topiramate [0 mg/day (placebo), 100 mg/day, 200 mg/day] and aripiprazole [0 mg/day (placebo), 7.5 mg/day, 15 mg/day] in 90 non-treatment seeking, heavy drinking, alcohol-dependent individuals. Main outcomes were the efficacy of 200 mg/day topiramate and 15 mg/day aripiprazole, alone and combined, in reducing drinks consumed during an alcohol self-administration procedure (human laboratory phase) and while receiving the study medications prior to the laboratory session (naturalistic drinking phase). Other outcomes in the laboratory phase included alcohol craving, and alcohol biphasic effects. In the human laboratory phase, topiramate 200 mg/day reduced alcohol craving [**P < 0.01] and amplified alcohol-induced stimulation [*P < 0.05], but did not reduce the number of drinks consumed. Topiramate 200 mg/day was also effective in reducing drinking days [*P < 0.05], and alcohol craving [*P < 0.05], in the naturalistic drinking phase. No significant findings were found for aripiprazole for any of the outcomes analyzed. Participants receiving 200 mg/day topiramate reported reduced alcohol drinking and craving, and increased alcohol-related stimulation. These findings provide further support for the role of topiramate as a pharmacological treatment for AUD. NCT00884884 This study tested topiramate and aripiprazole alone and in combination. The results replicate past findings and suggest that topiramate may be an effective treatment for alcohol use disorder. The present results suggest that the combination of topiramate and aripiprazole do not warrant further evaluation.

29 April 2024 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
PSPaul S. Soliman
Paul S. Soliman
DCDallece E. Curley
Dallece E. Curley
CCChristy Capone
Christy Capone
EEErica Eaton
Erica Eaton
CHCarolina L Haass-Koffler
Carolina L Haass-Koffler